Patents Assigned to Institute For Antibodies Co., Ltd.
-
Patent number: 8540987Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.Type: GrantFiled: January 23, 2009Date of Patent: September 24, 2013Assignees: Institute for Antibodies Co., Ltd., Japan as Represented by Director-General of National Institute of Infectious Diseases, Osaka Prefecture University Public CorporationInventors: Masachika Azuma, Motohide Takahashi, Shunji Kozaki, Masafumi Mukamoto, Tomoko Kohda, Gene Kurosawa, Yoshikazu Kurosawa
-
Publication number: 20120046451Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: September 21, 2011Publication date: February 23, 2012Applicants: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Patent number: 8048992Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: GrantFiled: February 22, 2006Date of Patent: November 1, 2011Assignees: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Publication number: 20110014211Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.Type: ApplicationFiled: January 23, 2009Publication date: January 20, 2011Applicants: Institute for Antibodies Co., Ltd., Japan as Represented by Director-General of National Institute of Infectious Disesases, Osaka Prefecture University Public CorporationInventors: Masachika Azuma, Motohide Takahashi, Shunji Kozaki, Masafumi Mukamoto, Tomoko Kohda, Gene Kurosawa, Yoshikazu Kurosawa
-
Publication number: 20090203538Abstract: It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer.Type: ApplicationFiled: January 9, 2009Publication date: August 13, 2009Applicant: Institute for Antibodies Co., Ltd.Inventors: Atsushi Sugioka, Mototaka Sugiura, Yasushi Akahori, Nobuhiro Hayashi, Akihiko Takasaki, Miwa Morita, Gene Kurosawa, Mariko Sumitomo, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Noriko Satou, Masachika Azuma, Yoshinori Ukai, Kazuhiro Suzuki, Yoshikazu Kurosawa, Miho Tanaka, Mamoru Shiraishi
-
Publication number: 20090053243Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: February 22, 2006Publication date: February 26, 2009Applicant: Institute for Antibodies Co., LtdInventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Patent number: 7371849Abstract: The present invention provides camel antibody libraries that maintain in vivo diversity of camelid antibody variable region genes. The in vivo diversity of antibody variable region genes can be accomplished by, for example, mixing genes derived from a plurality of animals or modifying gene amplification conditions. Conventional methods yield only VHHs with limited repertoire diversity. However, the present invention provides libraries comprising genes encoding functional VHHs with sufficient repertoire size. According to the present invention, libraries that enable to freely obtain VHHs against arbitrary antigens are provided. VHHs have excellent solubility and stability, and show a reactivity that usually cannot be expected from tetrameric IgGs.Type: GrantFiled: September 13, 2002Date of Patent: May 13, 2008Assignee: Institute For Antibodies Co., Ltd.Inventors: Toshio Honda, Yasushi Akahori, Yoshikazu Kurosawa
-
Publication number: 20050037421Abstract: The present invention provides camel antibody libraries that maintain in vivo diversity of camelid antibody variable region genes. The in vivo diversity of antibody variable region genes can be accomplished by, for example, mixing genes derived from a plurality of animals or modifying gene amplification conditions. Conventional methods yield only VHHs with limited repertoire diversity. However, the present invention provides libraries comprising genes encoding functional VHHs with sufficient repertoire size. According to the present invention, libraries that enable to freely obtain VHHs against arbitrary antigens are provided. VHHs have excellent solubility and stability, and show a reactivity that usually cannot be expected from tetrameric IgGs.Type: ApplicationFiled: September 13, 2002Publication date: February 17, 2005Applicant: Institute For Antibodies Co., LTDInventors: Toshio Honda, Yasushi Akahori, Yoshikazu Kurosawa